SCHEMBL49259

SCHEMBL49259

C1=C([N]C2=CCCCC2)CCCC1

nearest known ligand 0.34

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.34
HDAC4 P56524 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
PSMB5 P28074 2/20 0.30
PSMB1 P20618 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL49444 0.91 HDAC3 (0.31) HDAC4HDAC2HDAC8HDAC6
SCHEMBL9350737 0.82 KDM1A (0.34) KDM1AHDAC4HDAC2HDAC8HDAC6
SCHEMBL9351364 0.80 KDM1A (0.33) KDM1AHDAC4HDAC2HDAC8HDAC6
SCHEMBL9350743 0.78
SCHEMBL1966089 0.78
SCHEMBL5807457 0.78
SCHEMBL9751277 0.78
SCHEMBL9882026 0.78
SCHEMBL9351369 0.76
SCHEMBL9751195 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150266839-A1 CYCLIC AMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-09-24 US disclosed
US-20150225392-A1 CYCLIC AMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-08-13 US disclosed
US-9072758-B2 Cyclic amide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-07-07 US disclosed
US-9040525-B2 Cyclic amide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-05-26 US disclosed
US-8765752-B2 3-hydroxyisothiazole 1-oxide derivatives MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2014-07-01 US disclosed
EP-2703394-A1 NOVEL 3-HYDROXYISOTHIAZOLE 1-OXIDE DERIVATIVE Mochida Pharmaceutical Co., Ltd. (JP) 2014-03-05 EP disclosed
EP-2703393-A1 CYCLIC AMIDE DERIVATIVE Mochida Pharmaceutical Co., Ltd. (JP) 2014-03-05 EP disclosed
US-20140057871-A1 CYCLIC AMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2014-02-27 US disclosed
US-8629102-B2 3-hydroxyisothiazole 1-oxide derivatives MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2014-01-14 US disclosed
US-8557766-B2 3-hydroxyisothiazole 1-oxide derivatives MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2013-10-15 US disclosed
US-8013052-B2 Curable resin, production method thereof, epoxy resin composition, and electronic device HITACHI CHEMICAL COMPANY, LTD. (JP) 2011-09-06 US disclosed
US-20090062460-A1 CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, METHOD FOR PRODUCING CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, CURING ACCELERATOR, CURABLE RESIN COMPOSITION, AND ELECTRONIC COMPONENT DEVICE HITACHI CHEMICAL CO., LTD. (JP) 2009-03-05 US disclosed
US-20090023855-A1 NOVEL CURABLE RESIN, PRODUCTION METHOD THEREOF, EPOXY RESIN COMPOSITION, AND ELECTRONIC DEVICE RESONAC CORPORATION (JP) 2009-01-22 US disclosed
US-7250211-B1 Polypropylene films and multilayered laminate IDEMITSU KOSAN CO., LTD. (JP) 2007-07-31 US disclosed
EP-1231226-B1 CALENDERED OR INJECTION MOLDED ARTICLE OUT OF POLYPROPYLENE IDEMITSU KOSAN CO (JP) 2006-08-02 EP disclosed
US-6770355-B1 USABLE AS A SUBSTITUTE FOR SOFT VINYL CHLORIDE FILMS IDEMITSU PETROCHEMICAL CO., LTD. (JP) 2004-08-03 US disclosed
US-6734270-B1 Polypropylene-based calendered article and injection-molded article IDEMITSU PETROCHEMICAL CO., LTD. (JP) 2004-05-11 US disclosed
EP-1241206-A1 POLYPROPYLENE FILM AND MULTILAYERED LAMINATE IDEMITSU PETROCHEMICAL CO., LTD. (JP) 2002-09-18 EP disclosed
EP-1231226-A1 ROLLED POLYPROPYLENE AND INJECTION-MOLDED POLYPROPYLENE IDEMITSU PETROCHEMICAL CO., LTD. (JP) 2002-08-14 EP disclosed
EP-1231236-A1 POLYPROPYLENE FILM AND MULTILAYERED LAMINATE IDEMITSU PETROCHEMICAL CO., LTD. (JP) 2002-08-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266839-A1 CYCLIC AMIDE DERIVATIVE GPR119, NR0B1, NR4A1 KDM1A 1720/4885HDAC4 887/4885HDAC2 1466/4885
US-20140057871-A1 CYCLIC AMIDE DERIVATIVE GPR119, NR0B1, NR4A1 KDM1A 1650/4885HDAC4 854/4885HDAC2 1465/4885
US-20150225392-A1 CYCLIC AMIDE DERIVATIVE GPR119, NR0B1, NR2C2 KDM1A 2428/4885HDAC4 735/4885HDAC2 769/4885
US-20090062460-A1 CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, METHOD FOR PRODUCING CURING ACCELERATING COMPOUND-SILICA COMPOSITE MATERIAL, CURING ACCELERATOR, CURABLE RESIN COMPOSITION, AND ELECTRONIC COMPONENT DEVICE NCAPH, RAD51, H1-2 KDM1A 368/4885HDAC4 1312/4885HDAC2 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.